Dallas, TX (PRWEB) December 24, 2014
The report “Erbitux (Colorectal Cancer) – Forecast and Market Analysis to 2023” focuses on the current treatment landscape, unmet needs, current pipeline and commercial opportunities in the colorectal cancer market. The drug Erbitux is used for the treatment of metastatic colorectal cancer. It is an epidermal growth factor receptor inhibitor which is also used for the treatment of head and neck cancer, and lung cancer. The drug received FDA approval in 2009 and it is given in combination with chemotherapy. Erbitux binds to epidermal growth factor receptor and turns off the uncontrolled growth in cancers with epidermal growth factor receptor mutations. Some of the side effects of this drug are photosensitivity, dizziness, rash, fever, wheezing and hypotension. However, most of these side effects can be managed or reduced with medications. Complete Report is Available @ http://www.rnrmarketresearch.com/erbitux-colorectal-cancer-forecast-and-market-analysis-to-2023-market-report.html .
In February 2004, Eli Lilly BMS Merck KGaA’s Erbitux (cetuximab) became the first monoclonal antibody to be approved by the FDA for metastatic CRC. The recombinant chimeric IgG1 monoclonal antibody was the first of a novel class of antibodies that target the EGFR pathway. Overexpression of the epidermal growth factor receptor is frequent in CRC, where it contributes to activate genes that drive the cell cycle and mitosis. The binding of Erbitux to EGFR inhibits the downstream signaling of the receptor and hence reduces tumor progression and initiates cell cycle arrest.
- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Erbitux including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Erbitux for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.
Order a Purchase copy of report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=251702 .
Table of Contents
1 Table of Contents
1.1 List of Tables
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.2 Clinical Staging
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Screening and Diagnosis
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice
5 Competitive Assessment
6 Erbitux (Cetuximab)
6.4 SWOT Analysis
7.4 Forecasting Methodology
7.4.1 Diagnosed Colorectal Cancer Patients
7.4.2 Percent Drug-Treated Patients
7.4.3 General Pricing Assumptions
7.4.4 Average Body Weight and Surface Area Across the 8MM
7.4.5 Individual Drug Assumptions
7.4.6 Generic Erosion
7.5 Primary Research - KOLs Interviewed for this Report
7.6 Primary Research - Prescriber Survey
7.7 About the Authors
7.7.2 Global Head of Healthcare
7.8 About GlobalData
List of Tables
Table 1: TNM and Staging Classification System for CRC
Table 2: Symptoms of Colorectal Cancer
Table 3: Treatment Guidelines for CRC
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013
Table 6: Leading Treatments for CRC, 2014
Table 7: Product Profile Erbitux
Table 8: Erbitux SWOT Analysis, 2014
Table 9: Global Sales Forecast ($m) for Erbitux, 2013-2023
Table 10: Average Body Weight and Surface Area Across the 8MM
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
Explore more reports on Cancer Drugs industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/cancer-drugs .
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.